Related Experiment Videos
Hemodynamic changes following long-term administration of CS-905, a novel dihydropyridine calcium blocker, in
K Oizumi1, H Nishino, S Miyake
1Sankyo Biological Research Laboratories, Sankyo Co., Ltd., Tokyo, Japan.
Insights
Long-term use of CS-905, a novel calcium blocker, effectively lowers blood pressure and prevents cardiac hypertrophy in hypertensive rats. This hypertension treatment improves cardiac output and regional blood flow without developing tolerance.
Area of Science:
- Pharmacology
- Cardiovascular Physiology
- Hypertension Research
Background:
- Spontaneously hypertensive rats (SHRs) are a common model for studying essential hypertension.
- Long-term hemodynamic effects of novel antihypertensive agents require thorough investigation.
- Calcium channel blockers are a cornerstone therapy for hypertension, but long-term efficacy and safety profiles vary.
Purpose of the Study:
- To evaluate the central and regional hemodynamic effects of chronic administration of CS-905, a novel calcium blocker.
- To determine if CS-905 exhibits sustained antihypertensive efficacy without inducing tolerance.
- To assess the impact of CS-905 on cardiac hypertrophy and organ-specific blood flow.
Main Methods:
- Administration of CS-905 (1 and 3 mg/kg/day) to spontaneously hypertensive rats for 15 weeks.
- Hemodynamic parameters were assessed using the radioactive microsphere technique at the end of the dosing period.
- Cardiac hypertrophy was evaluated, and regional organ blood flows were measured.
Main Results:
- CS-905 demonstrated a sustained, dose-dependent antihypertensive effect over 15 weeks.
- No tolerance to the antihypertensive effect of CS-905 was observed.
- The agent significantly reduced blood pressure and total peripheral resistance while increasing cardiac output.
- CS-905 prevented cardiac hypertrophy and increased blood flow to the kidney and brain without decreasing flow to any organ.
Conclusions:
- Chronic administration of CS-905 provides sustained blood pressure control in hypertensive rats.
- CS-905 offers potential benefits for long-term hypertension therapy by improving hemodynamics and preventing cardiac remodeling.
- The favorable regional blood flow profile suggests a potentially safe therapeutic option for managing hypertension.
Abstract:
To investigate the central and regional hemodynamics after long-term administration of CS-905, a novel calcium blocker, we administered the agent (1 and 3 mg/kg/day) for 15 weeks in spontaneously hypertensive rats. At the end of the dosing period, hemodynamic changes were examined using the radioactive microsphere technique. CS-905 produced a sustained dose-dependent antihypertensive effect without inducing tolerance during the 15-week dosing period and prevented cardiac hypertrophy. The agent increased cardiac output, decreased blood pressure and thus decreased total peripheral resistance in a dose-related manner. Regional blood flows measured by the microsphere technique were increased in the kidney and brain despite the lowered blood pressure. There was no organ where regional blood flow was decreased. These changes after chronic treatment with CS-905 would be beneficial in the long-term therapy of hypertension.